Last updated: 2026-09-16 14:41:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Lipocine Inc. (LPCN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,20, with a market capitalisation of $18,30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,81 to $12,37. This page covers its latest market performance, valuation, price trends and company information.
$18,30M | |
$2,21 | |
$326,91 | |
$1,81 | |
$2,19 | |
8,52K | |
43,94K | |
-- | |
$12,37 | |
$1,81 | |
-- | |
-- |
Lipocine Inc. (LPCN) is currently trading at $2,20 as of 2026-09-16 14:19:00, up 0,46% ($0,01) from the previous close of $2,19
During today's regular trading session, LPCN has traded between $1,81 and $326,91, with a trading volume of 8,52K shares. The current price is near the lower end of today's range.
Over the past seven days, Lipocine Inc. (LPCN) moved from $2,45 to $2,20, representing a decline of 10,41% ($0,26).
The stock traded between $2,15 and $2,48 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 20,95 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3,6%
LPCN is currently trading at $2,20, placing it 3,6% of the way from its 52-week low of $1,81 to its 52-week high of $12,37. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lipocine Inc. (LPCN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.